EP1885380A4 - Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis - Google Patents

Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis

Info

Publication number
EP1885380A4
EP1885380A4 EP06732912A EP06732912A EP1885380A4 EP 1885380 A4 EP1885380 A4 EP 1885380A4 EP 06732912 A EP06732912 A EP 06732912A EP 06732912 A EP06732912 A EP 06732912A EP 1885380 A4 EP1885380 A4 EP 1885380A4
Authority
EP
European Patent Office
Prior art keywords
metastasis
treatment
pharmaceutical compositions
sodium salt
arsenous acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06732912A
Other languages
German (de)
French (fr)
Other versions
EP1885380A1 (en
EP1885380B1 (en
Inventor
Sang-Bong Lee
Yong-Jin Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kominox Inc
Original Assignee
Komipharm International Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP16162414.3A priority Critical patent/EP3067068B1/en
Application filed by Komipharm International Co Ltd filed Critical Komipharm International Co Ltd
Priority to PL16162414T priority patent/PL3067068T3/en
Priority to PL06732912T priority patent/PL1885380T3/en
Priority to EP06732912A priority patent/EP1885380B1/en
Priority to SI200631444T priority patent/SI1885380T1/en
Publication of EP1885380A1 publication Critical patent/EP1885380A1/en
Publication of EP1885380A4 publication Critical patent/EP1885380A4/en
Application granted granted Critical
Publication of EP1885380B1 publication Critical patent/EP1885380B1/en
Priority to CY20121100940T priority patent/CY1113475T1/en
Priority to CY20191101162T priority patent/CY1122522T1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Luminescent Compositions (AREA)
  • Otolaryngology (AREA)
EP06732912A 2005-05-09 2006-05-09 Sodium meta-arsenite for use in the treatment of metastatic neoplastic diseases Active EP1885380B1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PL16162414T PL3067068T3 (en) 2005-05-09 2006-05-09 Sodium meta arsenite for use in the treatment of multiple myeloma
PL06732912T PL1885380T3 (en) 2005-05-09 2006-05-09 Sodium meta-arsenite for use in the treatment of metastatic neoplastic diseases
EP06732912A EP1885380B1 (en) 2005-05-09 2006-05-09 Sodium meta-arsenite for use in the treatment of metastatic neoplastic diseases
SI200631444T SI1885380T1 (en) 2005-05-09 2006-05-09 Sodium meta-arsenite for use in the treatment of metastatic neoplastic diseases
EP16162414.3A EP3067068B1 (en) 2005-05-09 2006-05-09 Sodium meta arsenite for use in the treatment of multiple myeloma
CY20121100940T CY1113475T1 (en) 2005-05-09 2012-10-10 Sodium-male Sodium for use in the treatment of migratory neoplastic diseases
CY20191101162T CY1122522T1 (en) 2005-05-09 2019-11-06 META ARSENICODE SODIUM FOR USE IN THE MANAGEMENT OF MULTIPLE MYELOMA

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05076071A EP1721615A1 (en) 2005-05-09 2005-05-09 Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
PCT/KR2006/001731 WO2006121280A1 (en) 2005-05-09 2006-05-09 Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis
EP06732912A EP1885380B1 (en) 2005-05-09 2006-05-09 Sodium meta-arsenite for use in the treatment of metastatic neoplastic diseases

Related Child Applications (3)

Application Number Title Priority Date Filing Date
EP14166070.4A Division EP2762145A1 (en) 2005-05-09 2006-05-09 Sodium meta arsenite for use in the treatment of pain and/or inflammation associated with cancer
EP16162414.3A Division EP3067068B1 (en) 2005-05-09 2006-05-09 Sodium meta arsenite for use in the treatment of multiple myeloma
EP11165670.8 Division-Into 2011-05-11

Publications (3)

Publication Number Publication Date
EP1885380A1 EP1885380A1 (en) 2008-02-13
EP1885380A4 true EP1885380A4 (en) 2009-02-18
EP1885380B1 EP1885380B1 (en) 2012-07-11

Family

ID=35197739

Family Applications (5)

Application Number Title Priority Date Filing Date
EP05076071A Withdrawn EP1721615A1 (en) 2005-05-09 2005-05-09 Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
EP16162414.3A Active EP3067068B1 (en) 2005-05-09 2006-05-09 Sodium meta arsenite for use in the treatment of multiple myeloma
EP11165670.8A Ceased EP2361628A1 (en) 2005-05-09 2006-05-09 Pharmaceutical compositions comprising of sodium meta-arsenite for use in the treatment of leukemia and lymphoma
EP06732912A Active EP1885380B1 (en) 2005-05-09 2006-05-09 Sodium meta-arsenite for use in the treatment of metastatic neoplastic diseases
EP14166070.4A Ceased EP2762145A1 (en) 2005-05-09 2006-05-09 Sodium meta arsenite for use in the treatment of pain and/or inflammation associated with cancer

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EP05076071A Withdrawn EP1721615A1 (en) 2005-05-09 2005-05-09 Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
EP16162414.3A Active EP3067068B1 (en) 2005-05-09 2006-05-09 Sodium meta arsenite for use in the treatment of multiple myeloma
EP11165670.8A Ceased EP2361628A1 (en) 2005-05-09 2006-05-09 Pharmaceutical compositions comprising of sodium meta-arsenite for use in the treatment of leukemia and lymphoma

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14166070.4A Ceased EP2762145A1 (en) 2005-05-09 2006-05-09 Sodium meta arsenite for use in the treatment of pain and/or inflammation associated with cancer

Country Status (24)

Country Link
US (2) US20090011047A1 (en)
EP (5) EP1721615A1 (en)
JP (1) JP5026408B2 (en)
KR (3) KR20160035101A (en)
CN (2) CN101277707A (en)
AR (1) AR054448A1 (en)
AU (1) AU2006244767B2 (en)
BR (1) BRPI0608716A2 (en)
CA (3) CA2926846C (en)
CY (2) CY1113475T1 (en)
DK (2) DK3067068T3 (en)
ES (2) ES2394264T3 (en)
HK (1) HK1109736A1 (en)
HU (1) HUE046029T2 (en)
IL (3) IL187220A (en)
LT (1) LT3067068T (en)
PL (2) PL3067068T3 (en)
PT (1) PT1885380E (en)
RU (1) RU2401662C2 (en)
SG (5) SG10201602555WA (en)
SI (2) SI1885380T1 (en)
TW (5) TWI574692B (en)
WO (1) WO2006121280A1 (en)
ZA (1) ZA200710559B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US20120045520A1 (en) * 2008-08-21 2012-02-23 Sang Bong Lee Pharmaceutical composition comprising arsenite for the treatment of malignancy
RU2568834C2 (en) * 2009-09-10 2015-11-20 Коминокс, Инк. Anti-cancer therapy, directed against cancer stem cells and forms of cancer, resistant to treatment by medications
KR20120048706A (en) * 2009-09-18 2012-05-15 코미녹스 인코포레이티드 Methods for treating brain tumors
EP2524226A1 (en) 2010-01-13 2012-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Promyelocytic leukemia protein as a redox sensor
WO2012095379A1 (en) * 2011-01-11 2012-07-19 Universität Basel Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
KR101309844B1 (en) * 2013-03-15 2013-09-23 박상채 Herbal medicine for enhancing anticancer activity and manufacturing method thereof
RU2618405C1 (en) * 2015-12-31 2017-05-03 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Method for adjuvant chemotherapy duration determination in case of locally advanced colorectal cancer with metastases in regional lymph nodes after radical surgery
US10806768B2 (en) * 2016-05-26 2020-10-20 Stephen N. Pitcher Composition for promoting metallothionein production
NZ752214A (en) 2016-12-01 2022-11-25 Eupharma Pty Ltd Arsenic compositions
AR114596A1 (en) * 2018-03-22 2020-09-23 Komipharm Int Australia Pty Ltd PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURE
WO2019234112A1 (en) * 2018-06-05 2019-12-12 Katholieke Universiteit Leuven Combination treatment of arsenic oxide and antiandrogens
CN115243692A (en) * 2020-02-16 2022-10-25 科微范国际澳大利亚私人有限公司 Methods of treatment using meta-arsenite
KR20220020635A (en) * 2020-08-12 2022-02-21 이상봉 External preparation composition for promoting hair growth or preventing hair loss
KR20220020637A (en) * 2020-08-12 2022-02-21 이상봉 Oral administration pharmaceutical composition for prevention of hair loss and improvement of hair growth comprising salt of meta-arsenite
KR20220020633A (en) * 2020-08-12 2022-02-21 이상봉 Injectable composition for promoting hair growth or preventing hair loss
CN112336746A (en) * 2020-10-23 2021-02-09 内蒙古科技大学包头医学院 Perfusion chemotherapeutic medicine for bladder cancer and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889048A (en) * 1994-02-18 1999-03-30 Vorobieva; Tamara Vasilievna Methods and compositions for treating defective cell functions
KR20020083458A (en) * 2001-04-28 2002-11-02 주식회사 한국미생물연구소 Anticancer drug composition containing arsenic acid sodium salt, salt of meta-arsenite or their mixture
WO2003086424A1 (en) * 2002-04-10 2003-10-23 Korea Microbiological Laboratories, Ltd. Pharmaceutical composition comprising arsenite for the treatment of malignancy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
FR2431686A1 (en) 1978-07-20 1980-02-15 Nestle Sa Soc Ass Tech Prod DOSING AND BALANCING MECHANISM AND FILLING MACHINE COMPRISING SUCH A MECHANISM
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
KR930001917A (en) * 1991-07-26 1993-02-22 김두석 Method of manufacturing malignant tumor treatment
DK1378240T3 (en) * 1997-10-15 2008-12-08 Polarx Biopharmaceuticals Inc Pharmaceutical compositions comprising arsenic trioxide for the treatment of multiple myeloma
ES2399480T3 (en) 1997-11-10 2013-04-01 Memorial Sloan-Kettering Cancer Center Production process of arsenic trioxide formulations
CN1233476A (en) * 1998-04-24 1999-11-03 陆道培 Medicine for treating acute leukemia, and method for preparing same
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
KR100632250B1 (en) * 2004-02-16 2006-10-11 정태호 Anticancer agent containing arsenic compound as an active ingredient
US20060104292A1 (en) 2004-11-15 2006-05-18 Gupta Vivek G System and methods for supporting multiple communications interfaces with single client interface
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
RU2568834C2 (en) 2009-09-10 2015-11-20 Коминокс, Инк. Anti-cancer therapy, directed against cancer stem cells and forms of cancer, resistant to treatment by medications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889048A (en) * 1994-02-18 1999-03-30 Vorobieva; Tamara Vasilievna Methods and compositions for treating defective cell functions
KR20020083458A (en) * 2001-04-28 2002-11-02 주식회사 한국미생물연구소 Anticancer drug composition containing arsenic acid sodium salt, salt of meta-arsenite or their mixture
WO2003086424A1 (en) * 2002-04-10 2003-10-23 Korea Microbiological Laboratories, Ltd. Pharmaceutical composition comprising arsenite for the treatment of malignancy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HERNANDEZ-ZAVALA A ET AL: "Effects of arsenite on cell cycle progression in a human bladder cancer cell line", TOXICOLOGY, LIMERICK, IR, vol. 207, no. 1, 1 February 2005 (2005-02-01), pages 49 - 57, XP004675519, ISSN: 0300-483X *
KIM JA-YOUNG ET AL: "Involvement of p38 mitogen-activated protein kinase in the cell growth inhibition by sodium arsenite.", JOURNAL OF CELLULAR PHYSIOLOGY JAN 2002, vol. 190, no. 1, January 2002 (2002-01-01), pages 29 - 37, XP002506307, ISSN: 0021-9541 *
See also references of WO2006121280A1 *

Also Published As

Publication number Publication date
JP2008546640A (en) 2008-12-25
TWI386214B (en) 2013-02-21
KR20080030559A (en) 2008-04-04
WO2006121280A1 (en) 2006-11-16
TW201540306A (en) 2015-11-01
CY1122522T1 (en) 2021-01-27
BRPI0608716A2 (en) 2010-12-07
EP3067068A1 (en) 2016-09-14
HUE046029T2 (en) 2020-01-28
ZA200710559B (en) 2008-10-29
TW201302208A (en) 2013-01-16
RU2007145489A (en) 2009-06-20
CN104758312A (en) 2015-07-08
EP2762145A1 (en) 2014-08-06
TW201615200A (en) 2016-05-01
SG177983A1 (en) 2012-02-28
ES2394264T3 (en) 2013-01-30
DK3067068T3 (en) 2019-11-18
TWI539957B (en) 2016-07-01
DK1885380T3 (en) 2012-10-22
KR20150085122A (en) 2015-07-22
RU2401662C2 (en) 2010-10-20
PL3067068T3 (en) 2020-08-10
JP5026408B2 (en) 2012-09-12
LT3067068T (en) 2019-12-10
EP1885380A1 (en) 2008-02-13
IL229975A0 (en) 2014-01-30
CA2840609C (en) 2016-08-16
CA2926846C (en) 2019-04-02
AU2006244767B2 (en) 2011-06-16
EP3067068B1 (en) 2019-08-14
HK1109736A1 (en) 2008-06-20
SG10201405278SA (en) 2015-05-28
SG10202100785PA (en) 2021-02-25
AU2006244767A1 (en) 2006-11-16
EP1721615A1 (en) 2006-11-15
CA2840609A1 (en) 2006-11-16
IL244728A0 (en) 2016-04-21
IL187220A0 (en) 2008-02-09
SI1885380T1 (en) 2013-01-31
SG175633A1 (en) 2011-11-28
SI3067068T1 (en) 2020-02-28
PT1885380E (en) 2012-10-11
US20160199411A1 (en) 2016-07-14
TWI522105B (en) 2016-02-21
CY1113475T1 (en) 2016-06-22
CA2608035C (en) 2015-02-17
IL229975A (en) 2017-12-31
IL187220A (en) 2014-11-30
KR20160035101A (en) 2016-03-30
EP1885380B1 (en) 2012-07-11
TW201500046A (en) 2015-01-01
CA2926846A1 (en) 2006-11-16
SG10201602555WA (en) 2016-05-30
EP2361628A1 (en) 2011-08-31
US20090011047A1 (en) 2009-01-08
ES2754372T3 (en) 2020-04-17
TW200716144A (en) 2007-05-01
PL1885380T3 (en) 2013-02-28
AR054448A1 (en) 2007-06-27
CA2608035A1 (en) 2006-11-16
TWI574692B (en) 2017-03-21
KR101413731B1 (en) 2014-07-10
US11464859B2 (en) 2022-10-11
CN101277707A (en) 2008-10-01

Similar Documents

Publication Publication Date Title
IL229975A0 (en) Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis
IL185517A0 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
IL192763A (en) Pyrimidine derivatives, compositions comprising them and use thereof for the manufacture of medicaments for the treatment of cancer
ZA200803527B (en) Crystals of laquinimod sodium, and process for the manufacture thereof
IL199151A (en) Pyrimidine derivatives, pharmaceutical compositions comprising them, their use in the treatment of cancer and kits comprising them
EP1730163A4 (en) Pharmaceuticals salts of 3-o-(3,3-dimethylsuccinyl) betulinic acid
IL189737A0 (en) Pyrazine derivatives, their preparation and pharmaceutical compositions containing them
IL191984A0 (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
IL197941A0 (en) Use of anilinopyrimidine derivatives for the preparation of pharmaceutical compositions for treating non-alcoholic liver diseases
PT1860098E (en) Novel anthranilic acid derivative or salt thereof
TWI367761B (en) Pharmaceutical composition containing hardly water soluble pharmaceutical substance
PL1863495T3 (en) Calcium and sodium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate for treating cancer
HUP0600293A3 (en) Zinc salt of rosuvastatine, process for its preparation and pharmaceutical compositions containing it
EP1867640A4 (en) Agent for treatment of solid tumor
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
IL187655A0 (en) Anthranilic acid derivatives
EP1904088A4 (en) Compositions and methods for the treatment of cancer
IL194094A0 (en) Stable pharmacuetical compositions of 2-aza-bicyclol[3.3.0]-octane-3-carboxylic acid derivatives
IL198848A0 (en) Sodium salt of disaccharide compound, method for producing the same, and use of the same
IL190230A0 (en) Derivatives of 2-aminthiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals
IL187419A0 (en) Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
ZA200706710B (en) 6-Phenylhex-5-enoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions them, and therapeutic uses thereof
ZA200810524B (en) Pyrimidine derivatives useful in the treatment of cancer
AP2008004391A0 (en) Pharmaceutical composition suitable for the treatment of malaris within one day

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071207

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RADEMAKER, BERNARDUS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YANG, YONG-JIN

Inventor name: LEE, SANG-BONG

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1109736

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090119

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20090109BHEP

Ipc: A61K 33/36 20060101AFI20061129BHEP

17Q First examination report despatched

Effective date: 20090515

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KOMINOX, INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: SODIUM META-ARSENITE FOR USE IN THE TREATMENT OF METASTATIC NEOPLASTIC DISEASES

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 565729

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006030690

Country of ref document: DE

Effective date: 20120906

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20121004

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1109736

Country of ref document: HK

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20120402282

Country of ref document: GR

Effective date: 20121122

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2394264

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20130130

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 12971

Country of ref document: SK

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E007310

Country of ref document: EE

Effective date: 20121010

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20130412

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E015511

Country of ref document: HU

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006030690

Country of ref document: DE

Effective date: 20130412

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: EE

Ref legal event code: HC1A

Ref document number: E007310

Country of ref document: EE

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230614

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240527

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240526

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20240418

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240527

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240527

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20240418

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240530

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20240422

Year of fee payment: 19

Ref country code: DK

Payment date: 20240527

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240529

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240602

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240603

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20240423

Year of fee payment: 19

Ref country code: AT

Payment date: 20240419

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20240418

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20240425

Year of fee payment: 19

Ref country code: FR

Payment date: 20240527

Year of fee payment: 19

Ref country code: FI

Payment date: 20240527

Year of fee payment: 19

Ref country code: EE

Payment date: 20240422

Year of fee payment: 19

Ref country code: CY

Payment date: 20240422

Year of fee payment: 19

Ref country code: BG

Payment date: 20240510

Year of fee payment: 19

Ref country code: SI

Payment date: 20240417

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240419

Year of fee payment: 19

Ref country code: PT

Payment date: 20240423

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240430

Year of fee payment: 19

Ref country code: SE

Payment date: 20240527

Year of fee payment: 19

Ref country code: LV

Payment date: 20240418

Year of fee payment: 19

Ref country code: HU

Payment date: 20240424

Year of fee payment: 19

Ref country code: BE

Payment date: 20240527

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240521

Year of fee payment: 19